Stocks · Health care · Pharmaceutical Preparations

Theravance Biopharma, Inc.

TBPH Clue Score61
United States Fiscal year ends December CIK 0001583107 Results filed 10 Aug 2026

What the insiders did Net buying

Insider
Date
Role
Action
Shares
Price
Amount
Eran Broshy
26 Nov 2025
Director
Sold after exercise
15,501
$20.00
$310.02K
Eran Broshy
26 Nov 2025
Director
Sold after exercise
14,000
$20.00
$280.00K
Eran Broshy
11 Nov 2025
Director
Sold after exercise
14,000
$18.50
$259.00K
Eran Broshy
11 Nov 2025
Director
Sold after exercise
15,500
$17.00
$263.50K
Eran Broshy
11 Nov 2025
Director
Sold after exercise
29,500
$18.50
$545.75K

What was left out

Form 4 filings counted 515
Amendments (4/A) skipped 1
Filings about a different issuer 0
Unreadable filings 1
Joint filings 1
Sales on a Rule 10b5-1 plan 26
Sales straight out of an exercise 5
Sales at will 44
Transactions with no price 0
Shares from compensation/vesting 30,222,989
Sales filed before the plan box existed 35
History held since 19 May 2014